Adilen Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adilen Cruz has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Allison Verbyla
Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication - Almira Sejdic
Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication - Amy Sobel
Charlotte Radiology, Charlotte, NC
1 shared publication - Amy Voci
Department of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication - Cecilia Flynn
Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication - Chad Livasy
Department of Pathology, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication
Latest Publications
- Open Access
- 24 May 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (6) , 998-1006
A Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P P P P P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.
- 24 May 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (6) , 998-1006
Open AccessA Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P P P P P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.